TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21109670
Drug: Values affirmation
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Values affirmation intervention (students wrote about their most important values, twice at the beginning of the course)
Study: 12548129
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1 g every 8 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Study: 12548129
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg every 6 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Study: 7261627
Drug: Estrogen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen treatment group
Study: 23994192
Drug: Placebo sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sertraline
Study: 20515580
Drug: Forskolin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forskolin (10 mg capsule orally per day)
Study: 12073665
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg bd and clarithromycin 500 mg bd for 14 days
Study: 12073665
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg bd, clarithromycin 500 mg bd and amoxycillin 1 g bd for 7 days
Study: 10091625
Drug: Write continuously
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Write continuously for 30 min after btx A injection
Study: 10091625
Drug: Rest for
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest for 30 min after btx A injection
Study: 10091625
Drug: Btx A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Btx A treatment
Study: 7789082
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 564.5 mg/day as add-on therapy (plus CBZ)
Study: 2128415
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg PO 90 min before TRH)
Study: 371348
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexamethasone therapy (1 mg/kg) within six hours of injury, repeated at six hours, maintained at 1 mg/kg/day for eight days.
Study: 371348
Drug: None or
Normalized name: idebenone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: None or low dose regimen (0.25 mg/kg/day).
Study: 27245155
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl trinitrate (GTN) spray
Study: 25313573
Drug: I40 -
Normalized name: TITANIUM DIOXIDE 400 mg in 10 g TOPICAL STICK [SHISEIDO THE MAKEUP FOUNDATION I40]
Approvals — FDA: no, EMA: no, PMDA: no
Description: I40 - Basal diet supplemented with 40 mg Cu/kg DM in the form of copper sulphate
Study: 25313573
Drug: O40 -
Normalized name: OCTINOXATE 1617 mg in 30 mL / TITANIUM DIOXIDE 825 mg in 30 mL TOPICAL CREAM [CLE DE PEAU BEAUTE RADIANT FLUID FOUNDATION O40]
Approvals — FDA: no, EMA: no, PMDA: no
Description: O40 - Basal diet supplemented with 40 mg Cu/kg DM in the form of copper proteinate
Study: 25313573
Drug: I10 -
Normalized name: SET,INFUSION ACCU-CHEK ULTRAFLEX-I10-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: I10 - Basal diet supplemented with 10 mg Cu/kg DM in the form of copper sulphate
Study: 25313573
Drug: O10 -
Normalized name: O10-Demethylcolchicine
DrugBank: Colchiceine (DB15534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O10 - Basal diet supplemented with 10 mg Cu/kg DM in the form of copper proteinate
Study: 25313573
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - Basal diet without supplementation of Cu (7 mg Cu/kg DM)
Study: 20596795
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg suspension via NG/NJ tube daily
Study: 20596795
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg IV q12 h
Study: 18046108
Drug: Irbesartan/Hydrochlorothiazide (HCTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/Hydrochlorothiazide (HCTZ) 300/25 mg
Study: 16126936
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg acetazolamide
Study: 25081290
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetazolamide
Study: 12403212
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (1,000 ng/ml)
Study: 12403212
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without growth hormone)
Study: 10090337
Drug: Epinephrine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (2 x 10(‐8) to 5 x 10(‐6) mol/L)
Study: 10090337
Drug: Endothelin‐1 (10(‐9)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin‐1 (10(‐9) mol/L)
Study: 1969115
Drug: Zidovudine 500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 500 mg per day
Study: 1969115
Drug: Zidovudine 1500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1500 mg per day
Study: 426989
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol formulation of etomidate
Study: 426989
Drug: Propylene glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylene glycol formulation of etomidate
Study: 426989
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection with pethidine premedication
Study: 31248548
Drug: Rivaroxaban plus
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban plus Aspirin
Study: 29153631
Drug: Brivaracetam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (all doses)
Study: 26639477
Drug: Micro emulsion
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro emulsion formulation
Study: 26639477
Drug: Gel formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel formulation
Study: 26639477
Drug: Ointment formulation
Normalized name: mineral oil / petrolatum / phenylephrine hydrochloride Rectal Ointment [Formulation R Ointment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment formulation
Study: 23742877
Drug: Aflibercept (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (6 mg/kg, intravenously every 3 weeks)
Study: 18071034
Drug: Pergolide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide treatment
Study: 10865186
Drug: C.E.S. (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.S. (synthetic mixture of estrogens; 2 x 0.625 mg)
Study: 10865186
Drug: Premarin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin (2 x 0.625 mg)
Study: 2871960
Drug: Naloxone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.1 mg/kg, intravenously)
Study: 2871960
Drug: Prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (10 mg, intravenously)
Study: 25686644
Drug: Rituximab (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (four weekly infusions of 375 mg/m(2))
Study: 25686644
Drug: Rituximab +
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab + interferon‐α2a (3‐4.5 MIU daily for 5 weeks)
Study: 8742215
Drug: Chymopapain (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chymopapain (first-line treatment)
Study: 1616080
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic therapy (intermittent intravenous morphine injections)
Study: 6091483
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g IV at start of anesthesia, followed by 1 g dose 24 hours later)
Study: 6091483
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g IV at start of anesthesia, followed by 1.5 g every 12 hours for 2 days)
Study: 6091483
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g IV at start of anesthesia)
Study: 26546051
Drug: Adjunct treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct treatment with intravitreal and subtenons triamcinolone acetonide, oral flurbiprofen, and guttae prednisolone acetate 1%
Study: 24681717
Drug: MoodGYM (5-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoodGYM (5-week computerized cognitive behavior therapy program)
Study: 18044284
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus administration of cisatracurium (Group A, n = 30)
Study: 18044284
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cisatracurium (Group B, n = 30)
Study: 11896038
Drug: Acetaminophen (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (therapeutic dose)
Study: 24607801
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current therapy (ICT)
Study: 27223846
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg once-daily
Study: 27223846
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once-daily
Study: 18226725
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Nitrous oxide-oxygen mixture (ME)
Study: 11048472
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sustained-release diltiazem
Study: 8905026
Drug: Doxorubicin (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50, 60 mg/m2) followed by paclitaxel (155, 175 mg/m2) every 3 weeks
Study: 29324186
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (CIT) ingestion (600 mg·kg‐1) during recovery
Study: 19120293
Drug: Parenteral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral insulin
Study: 8607507
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (660 mg/d)
Study: 8607507
Drug: acetaminophen (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen (4000 mg/d)
Study: 8607507
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (660 mg/d) in subjects with endoscopic changes
Study: 8607507
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (660 mg/d) in subjects without endoscopic damage
Study: 2015153
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Clonidine 150 micrograms and Flunitrazepam 1 mg)
Study: 22902185
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose B vitamins
Study: 21975348
Drug: JNJ-38431055 (2.5-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38431055 (2.5-800 mg)
Study: 21975348
Drug: JNJ-38431055 (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38431055 (in graded glucose infusion study)
Study: 8985111
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 50 units of botulinum toxin type A (BTX‐A) into the mid belly of the gastrocnemius muscle (distally at three sites)
Study: 8985111
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 50 units of botulinum toxin type A (BTX‐A) into the proximal site near the muscular origin of the gastrocnemius muscle
Study: 1727998
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (0.15 mg/kg per dose)
Study: 6319452
Drug: Fenfluramine (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (0.5, 1.0, and 1.5 mg/kg)
Study: 6319452
Drug: Cyproheptadine (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (serotonin antagonist) pretreatment before fenfluramine administration
Study: 12874612
Drug: Telemedical home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedical home blood pressure (HBP) measurement (5 days, four times daily)
Study: 1560163
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (400 mg tablet)
Study: 22560357
Drug: Analgesic change
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic change (following TEC)
Study: 18354285
Drug: FS 4IU
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS 4IU VH S/D (fibrin sealant containing 4 IU/ml thrombin)
Study: 17022376
Drug: Anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation treatment for 6 weeks
Study: 17022376
Drug: Anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation treatment for 12 weeks
Study: 10952474
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg once daily in the morning
Study: 10952474
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 microg once daily in the evening
Study: 6508324
Drug: Bestatin (B)
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin (B) with maintenance chemotherapy
Study: 6508324
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy alone (C)
Study: 6508324
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy alone (C) in patients over 50 years of age
Study: 31013182
Drug: Olanzapine (OLN)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLN) 10 mg orally on days 1 to 4
Study: 31013182
Drug: Haloperidol (HAL)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (HAL) 1 mg orally on day 1 and 0.5 mg twice daily on days 2 to 4
Study: 29494473
Drug: Tablet-based audiometric
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based audiometric applications
Study: 23019940
Drug: Compound Zhebei
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Zhebei Granule (CZG)
Study: 12069174
Drug: 370 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 microg budesonide PulmoSphere inhaled from Eclipse DPI at target PIF of 25 L x min(‐1) (PSbud25)
Study: 12069174
Drug: 370 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 microg budesonide PulmoSphere inhaled from Eclipse DPI at target PIF of 50 L x min(‐1) (PSbud50)
Study: 12069174
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg of pelletized budesonide from Pulmicort Turbuhaler at 60 L x min(‐1) (THbud60)
Study: 10417522
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment with diisopropyl adipate
Study: 10417522
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment without diisopropyl adipate
Study: 10417522
Drug: 0.1% Betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Betamethasone 17alpha-valerate ointment
Study: 10417522
Drug: 0.005% Calcipotriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% Calcipotriol ointment
Study: 7752328
Drug: Topical prostaglandin‐E1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin‐E1
Study: 6994775
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg orally
Study: 6994775
Drug: 2.3 mg
Normalized name: menthol 2.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3 mg intravenously
Study: 6994775
Drug: Multiple dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing
Study: 30341026
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (own dry eye treatment regimen)
Study: 28386990
Drug: iGlarLixi (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi (insulin glargine 100 U plus lixisenatide)
Study: 28828532
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 µg/kg)
Study: 19252348
Drug: L-thyroxin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxin treatment before and after
Study: 17255299
Drug: High-dose bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bolus interleukin 2 (IL-2)
Study: 17255299
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of IL-2 (either alone or in combination with IFN)
Study: 17255299
Drug: High-dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-2 therapy
Study: 15208972
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (comparison group)
Study: 9713297
Drug: Epidoxorubicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin (100 mg/m2) and Cyclophosphamide (600 mg/m2) on day 1 (group A)
Study: 23258640
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E + verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac
Study: 23258640
Drug: Verapamil (injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac
Study: 21275979
Drug: Intranasal lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lorazepam (0.1 mg/kg, maximum 4 mg)
Study: 21275979
Drug: Intravenous lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lorazepam (0.1 mg/kg, maximum 4 mg)
Study: 7954041
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg od, increased to 8 mg od if DBP > 90 mmHg)
Study: 7954041
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg [60 mg bid], increased to 360 mg [180 mg bid] if DBP > 90 mmHg)
Study: 3312113
Drug: Nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 80 mg OD
Study: 3312113
Drug: Nadolol 160
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 160 mg OD
Study: 3312113
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg bid
Study: 30009968
Drug: Fan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan therapy directed to the patient's face for five minutes
Study: 30009968
Drug: Fan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan therapy directed to the patient's legs (control group)
Study: 27506635
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of ezetimibe 10 mg plus rosuvastatin (5, 10, or 20 mg daily)
Study: 27506635
Drug: Rosuvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin alone (5, 10, or 20 mg daily)
Study: 29780263
Drug: Gel-200
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel-200
Study: 20213795
Drug: HELP-apheresis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HELP-apheresis plus standard treatment
Study: 15932816
Drug: Sertraline (N=23)
Normalized name: N-2,3-xylylanthranilic acid
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (N=23)
Study: 11464953
Drug: r‐metHuBDNF (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐metHuBDNF (doses >150 microg/day)
Study: 3533566
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dihydroergotamine (DHE)
Study: 3533566
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dihydroergotamine (DHE)
Study: 29408561
Drug: High-dose supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose supplemental vitamin D3 (2000 IU/day)
Study: 29408561
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1 g/day)
Study: 25479227
Drug: 940nm diode
Normalized name: Dioderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 940nm diode laser treatment
Study: 25479227
Drug: Bipolar radiofrequency
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bipolar radiofrequency therapy
Study: 24669646
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 0.2 mg + I/V fentanyl 2 microg/Kg
Study: 24669646
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo + I/V fentanyl 2 microg/Kg
Study: 16188207
Drug: Flax oil
Normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax oil (60 g)